Compare Bath & Body Works Inc (BBWI) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bath & Body Works Inc vs Summit Therapeutics Inc — how do they compare? Bath & Body Works Inc trades at $18.52 (market cap $3.81B), while Summit Therapeutics Inc trades at $15.25 (market cap $12.06B). The key difference: Summit Therapeutics Inc is far larger — about 3.2× Bath & Body Works Inc's market cap, and Bath & Body Works Inc pays a 4.24% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| BBWI | SMMT | |
|---|---|---|
Market Cap | $3.81B | $12.06B |
Sector | Consumer Cyclical | Health |
52-Week High | $31.87 | $26.98 |
52-Week Low | $14.85 | $12.55 |
Enterprise Value | $7.70B | $11.39B |
Dividend Yield | 4.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BBWI trades at $19.32, down 5.11% over 24 hours, with a bearish technical signal and key support at $19. The stock shows attractive valuation metrics, including a P/E of 5.36 and P/S of 0.54, with a net income margin of 10.03% for 2025. Recent developments include expansion into Brazil and a partnership with Ulta Beauty, while Q2 2026 earnings are anticipated on August 26, 2026.
The outlook presents a value opportunity given low valuations and strategic growth initiatives, but risks include declining revenue trends, high debt levels, and negative shareholder equity. Analyst consensus is mixed with a $22.11 price target, suggesting potential upside if turnaround efforts succeed amidst competitive and execution challenges.
Summit Therapeutics (SMMT) trades at $15.42, up 3.7% with a bullish technical signal. The company shows negative profitability with ROE at -192.5% and net loss of $1.08B for 2025, but maintains positive analyst sentiment with 14 buy ratings and a $27.90 consensus price target. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials.
The investment case hinges on ivonescimab's regulatory approval potential, offering significant upside if successful. However, substantial risks include ongoing losses, cash burn requiring financing, and regulatory uncertainty. Current technical strength suggests momentum, but fundamental challenges require careful risk assessment for speculative biotech investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bath & Body Works Inc
Bath & Body Works is a specialty home fragrance and fragrant body care retailer operating under the Bath & Body Works, C.O. Bigelow, and White Barn brands. The company generates most of its business in North America, with less than 5% of sales from international markets in fiscal 2021. For fiscal 2021, 72% of sales stemmed from the brick-and-mortar network (which is composed of more than 1,700 retail stores), up from 65% in 2020, as consumer shopping patterns began to return to normal. Future growth is expected from store reformatting, digital and international channels, as well as new category expansion.
Read more on BBWI →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
